LCB02A
LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.
Overview
LCB02A is a monoclonal antibody developed by LigaChem Biosciences. Its target is Claudin 18.2. ClinicalTrials.gov describes the intervention as: CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07460375, plans to enrol 191 participants with primary completion expected 2030-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"LCB02A" OR ABSTRACT:"LCB02A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LCB02A, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentLCB84
Shares LigaChem Biosciences and the tags pipeline, ctgov-ingest.
- TreatmentTAC01-CLDN18.2
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentBDC-4182
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentLB4330
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentRC118-ADC
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentAZD4360
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentSpevatamig
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentM108
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.